

PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITY

EINGANG/RECEIVED

19. Aug. 2005

Global Intellectual Property
ALTANA Pharma AG

PCT

To:

see form PCT/ISA/220

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY
(PCT Rule 43bis.1)

Date of mailing
(day/month/year) see form PCT/ISA/210 (second sheet)

Applicant's or agent's file reference
see form PCT/ISA/220

FOR FURTHER ACTION
See paragraph 2 below

International application No.
PCT/EP2005/050946

International filing date (day/month/year)
03.03.2005

Priority date (day/month/year)
03.03.2004

International Patent Classification (IPC) or both national classification and IPC
C07D221/12, A61K31/473, C07D401/10, C07D417/10

Applicant
ALTANA PHARMA AG

1. This opinion contains indications relating to the following items:

- ☒ Box No. I Basis of the opinion
- ☐ Box No. II Priority
- ☒ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI Certain documents cited
- ☐ Box No. VII Certain defects in the international application
- ☐ Box No. VIII Certain observations on the international application

2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA:



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized Officer

Fink, D

Telephone No. +49 89 2399-8701



**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.
PCT/EP2005/050946

Box No. I Basis of the opinion

1. With regard to the **language**, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
 - ☐ This opinion has been established on the basis of a translation from the original language into the following language , which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).
2. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
 - a. type of material:
 - ☐ a sequence listing
 - ☐ table(s) related to the sequence listing
 - b. format of material:
 - ☐ in written format
 - ☐ in computer readable form
 - c. time of filing/furnishing:
 - ☐ contained in the international application as filed.
 - ☐ filed together with the international application in computer readable form.
 - ☐ furnished subsequently to this Authority for the purposes of search.
3. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.
PCT/EP2005/050946

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application,
- ☒ claims Nos. 16 and 17 (as regards industrial applicability)

because:

- ☒ the said international application, or the said claims Nos. 16 and 17 relate to the following subject matter which does not require an international preliminary examination (*specify*):

see separate sheet

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☐ no international search report has been established for the whole application or for said claims Nos.
- ☐ the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:
 - the written form ☐ has not been furnished
 - ☐ does not comply with the standard
 - the computer readable form ☐ has not been furnished
 - ☐ does not comply with the standard
- ☐ the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-*bis* of the Administrative Instructions.
- ☐ See separate sheet for further details

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.
PCT/EP2005/050946

Box No. V Reasoned statement under Rule 43*bis*.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	1-17
	No: Claims	
Inventive step (IS)	Yes: Claims	1-5, 9, 11-17
	No: Claims	6-8, 10
Industrial applicability (IA)	Yes: Claims	1-15
	No: Claims	

2. Citations and explanations

see separate sheet

Re Item III.

The present **claims 16 and 17** relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT.

Consequently, no opinion will be formulated with respect to industrial applicability of the subject-matter of these claims.

[For the assessment of the aforesaid claims on the question whether they are industrially applicable, no unified criteria exist in the PCT. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but will allow, however, claims to a (known) *compound for first use in medical treatment* and the *use of such a compound for the manufacture of a medicament for a new medical treatment*.]

Re Item V.

Reference is made to the following documents:

D1: WO-A-00/42020 (20 July 2000);

D2: WO-A-99/05111 (4 February 1999);

D3: WO-A-2004/019944 (**11 March 2004**);

1. NOVELTY (Article 33(2) PCT):

The present application satisfies the criterion set forth in Article 33(2) PCT because the subject-matter of **claims 1-17** is new in respect of prior art as defined in the regulations (Rule 64(1)-(3) PCT):

The compounds of present **claims 1-12** are novel over the prior art **D1** and **D2** on account of the *oxy substituent* attached to either position 2 or 3 of the phenanthridine ring (cf., the definitions of the present substituent groups R4 and R5 according to which either R4 represents **-O-R41** (and R5 is hydrogen or 1-4C-alkyl) or R5 represents **-O-R51** (and R4 is hydrogen or 1-4C-alkyl)).

The present compounds are furthermore novel over **D3** (published on **11 March 2004**) on account of the present substituent group **R7** (the present 6-phenyl ring has to be substituted with a **monocyclic heterocycle**, whereas the 6-phenyl ring in **D3** may not be substituted with a heterocycle (cf., the definition of the substituent groups R6 and R7 according to claim 1 of **D3**)).

2. INVENTIVE STEP (Article 33(3) PCT):

The present application does not satisfy the criterion set forth in Article 33(3) PCT because the subject-matter of the present **claims 6-8** and **10** does not appear to involve an inventive step (Rule 65(1)(2) PCT):

2.1. the compounds of the present **claims 1-5, 11** and **12**:

It would appear that the present **claims 1-5, 11 and 12** are fully **entitled** to the presently claimed priority date of *03 March 2004*.

Accordingly, the document **D3** (published on *11 March 2004*) cannot be taken into account for the assessment of the question of inventive step.

The compounds of the present claim 1-5, 11 and 12 **differ** from the compounds of **D1** and **D2** in that they have an **oxy substituent** attached to either position 2 or 3 of the phenanthridine ring (cf., the definitions of the present substituent groups R4 and R5 according to which either R4 represents **-O-R41** (and R5 is hydrogen or 1-4C-alkyl) or R5 represents **-O-R51** (and R4 is hydrogen or 1-4C-alkyl)).

In the light of this prior art the **problem** to be solved by the present application resides in the provision of further 6-phenyl-1,2,3,4,4a,10b-hexahydrophenanthridine derivatives useful as *PDE4 inhibitors*.

The said problem has been **solved** by the compounds of the present **claim 1** (cf., the activity data (*PDE4 inhibition*) of table A on page 65 of the present description).

Given the fact that none of the available prior art documents suggests phenanthridine compounds with a 2- or 3- *oxy substituent*, it is considered that the present solution (i.e., the subject-matter of the present **claims 1-5, 11 and 12**) has to be regarded to be non-obvious in the sense of Article 33(3) PCT.

2.2. the compounds of the present **claims 6-10**:

It would further appear that the present **claims 6-9 and 10** (cf., the part on page 73, lines 11-36) are **not entitled** to the presently claimed priority date of *03 March 2004*.

Accordingly, the effective filing date of the subject-matter of the present claims 6-10 is *03 March 2005* (cf., the present filing date).

Hence the document **D3** (published on *11 March 2004*) may be taken into account for the assessment of the question of inventive step.

2.2.1. The compounds of the present **claims 6-8 and 10** differ from the compounds of e.g. **D2** - which may be considered to represent the **closest prior art** - essentially only in that they have an **oxy substituent** attached to the 2-position of the phenanthridine ring (cf., the definition of the present substituent group **R4 = -O-R41**).

In the light of **D2** the **problem** to be solved by the present application resides in the provision of further 6-phenyl-1,2,3,4,4a,10b-hexahydro-phenanthridine derivatives useful as *PDE4 inhibitors*.

The said problem has been **solved** by the compounds of the present **claim 1-12** (cf., the activity data (*PDE4 inhibition*) of table A on page 65 of the present description).

Having regard to the teaching of **D3** it is considered that this solution (i.e., the subject-matter of the present dependent **claims 6-8 and 10**) appears to be obvious in the sense of Article 33(3) PCT:

As it is known from **D3** (cf., claim 1 therein) that 6-phenyl-1,2,3,4,4a,10b-hexahydro-phenanthridin-**2-ol** derivatives (such as, for instance, the 6-(3,4-Bis-(cyclopropylmethoxy)phenyl)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-**2-ol** of the example 7) **as well as** 6-phenyl-1,2,3,4,4a,10b-hexahydro-phenanthridine derivatives (see, for example, the 6-3,4-Bis-(cyclopropylmethoxy)phenyl)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydrophenanthridine of the example 15 of the prior art **D1**) possess *PDE4 inhibitory* activity (cf., page 61, table A of **D3** and page 48, table A of **D1**), the skilled person would have expected that e.g. the correspondingly modified 8,9-dimethoxy-6-[4-(2-ethyl-2H-tetrazol-5-yl)phenyl]-1,2,3,4,4a,10b-hexahydro-phenanthridine of the example 4 of **D2** would display some *PDE4 inhibitory* activity.

Accordingly, it is considered that e.g. the 6-[4-(2-(1-4C-alkyl)-2H-tetrazol-5-yl)phenyl]-1,2,3,4,4a,10b-hexahydro-phenanthridin-**2-ol** derivatives of the present **claims 6-8 and 10** are obvious in the light of **D2** and **D3**.

2.2.2. The compounds of the present dependent **claim 9**, on the other hand, **differ** from the compounds of the prior art **D1 - D3** in that the 6-phenyl ring has to be substituted with a *pyridinyl* or *pyrimidinyl* group.

As none of the available prior art suggests 1,2,3,4,4a,10b-hexahydro-phenanthridin-2-*ol* with a 6-(*pyridinyl* or *pyrimidinyl*)phenyl- substituent, it is considered that the compounds of the present dependent **claim 9** may be regarded to be non-obvious in the sense of Article 33(3) PCT

3. INDUSTRIAL APPLICABILITY (Article 33(4) PCT):

The subject-matter of the present **claims 1-15** concerns chemical compounds, a pharmaceutical composition and the use of chemical compounds for the production of pharmaceutical compositions and is therefore considered to be industrial applicable in the sense of Article 33(4) PCT.